Mitchell L. Shiffman
0000-0002-3575-6516
Publication & Citation Trends
Most Cited Works
Publications
398 total
147 - VOLIXIBAT FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS: AN ADAPTIVE, RANDOMIZED, PLACEBOCONTROLLED PHASE 2B TRIAL (VANTAGE): 28-WEEK INTERIM RESULTS
Cited by 0
Semantic Scholar
138 - LONG-TERM TREATMENT WITH ELAFIBRANOR LEADS TO BIOCHEMICAL AND SYMPTOMATIC IMPROVEMENTS FOR AT LEAST 3 YEARS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS
Cited by 0
Semantic Scholar
Long-term efficacy and safety of elafibranor in primary biliary cholangitis: Interim results from the open-label extension of the ELATIVE trial up to 3 years
Cited by 1
Semantic Scholar
OS-089 Elafibranor for primary sclerosing cholangitis: the ELMWOOD phase II randomised controlled trial
Cited by 1
Semantic Scholar
784: VOLIXIBAT FOR THE TREATMENT OF CHOLESTATIC PRURITUS IN PRIMARY BILIARY CHOLANGITIS: AN ADAPTIVE, RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL (VANTAGE): INTERIM RESULTS
Cited by 0
Semantic Scholar
P199 Long-term efficacy and safety of elafibranor in primary biliary cholangitis: interim results from the open-label extension of the ELATIVE® trial
Cited by 0
Semantic Scholar
Safety and efficacy of elafibranor in primary sclerosing cholangitis: The ELMWOOD phase II randomized-controlled trial.
Cited by 9
Semantic Scholar
Research Topics
Liver Disease Diagnosis and Treatment
(268)
Hepatitis C virus research
(266)
Hepatitis B Virus Studies
(136)
Liver Disease and Transplantation
(84)
Liver Diseases and Immunity
(51)
Frequent Co-Authors
Affiliations
Linköping University
Human Genome Sciences (United States)
University of North Carolina at Chapel Hill
Roche (Switzerland)
Virginia Department of Education